Aeglea BioTherapeutics

Aeglea BioTherapeutics was founded in December 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

news image

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

news image

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More

DIAGNOSTICS

ZIVO BIOSCIENCE ANNOUNCE JOINING RUSSELL MICROCAP® INDEX MEMBERSHIP

Zivo | June 28, 2022

news image

ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022. Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and gr...

Read More

MEDTECH

AESTHETICS BIOMEDICAL® ANNOUNCES COLLABORATION WITH U.S. DERMATOLOGY PARTNERS OFFERING CONSUMERS LUXURY EXPERIENTIAL AESTHETIC TREATMENTS

Aesthetics Biomedical® Inc. | October 07, 2021

news image

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts...

Read More
news image

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More
news image

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More
news image

DIAGNOSTICS

ZIVO BIOSCIENCE ANNOUNCE JOINING RUSSELL MICROCAP® INDEX MEMBERSHIP

Zivo | June 28, 2022

ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022. Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and gr...

Read More
news image

MEDTECH

AESTHETICS BIOMEDICAL® ANNOUNCES COLLABORATION WITH U.S. DERMATOLOGY PARTNERS OFFERING CONSUMERS LUXURY EXPERIENTIAL AESTHETIC TREATMENTS

Aesthetics Biomedical® Inc. | October 07, 2021

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts...

Read More